{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-023648","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.750864+00:00","generated_at":"2026-05-18T19:02:09.488001+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CFO Nirav Jhaveri departs Opus Genetics; Amy Rabourn appointed interim principal financial officer","bullets":["CFO Nirav Jhaveri terminated without cause on June 25, 2025; no disagreement with auditors or management.","Jhaveri eligible for severance per employment agreement subject to separation release.","Amy Rabourn, SVP of Finance, serves as principal financial and accounting officer until successor appointed.","Rabourn has 20+ years finance experience, CPA, previously at Gemphire and Pfizer."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-023648","json":"https://secwatch.observer/filing/0001140361-25-023648.json","markdown":"https://secwatch.observer/filing/0001140361-25-023648.md","text":"https://secwatch.observer/filing/0001140361-25-023648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125023648/0001140361-25-023648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125023648/ef20051087_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:02:09.488001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}